Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
Recruiting1 awardPhase 1 & 2
Iowa City, Iowa
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
Chemotherapy
Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Gilbert, Arizona
This trial is testing the combination of pembrolizumab with different chemotherapies and/or other immunotherapy drugs to see if it is more effective and has fewer side effects than other treatments for people with squamous or non-squamous NSCLC.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Popular Filters
Trials for Non-Small Cell Lung Cancer Patients
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
Trials for NSCLC Patients
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
Trials for PD-L1 Positive Patients
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
SGN-PDL1V for Cancer
Recruiting1 awardPhase 1
San Antonio, Texas
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Monoclonal Antibodies
AZD7789 for Cancer
Recruiting1 awardPhase 1 & 2
Atlanta, Georgia
This trial is testing a new medicine called AZD7789 that helps the immune system fight advanced solid tumors by blocking proteins that hide cancer cells. It aims to see if the medicine is safe and effective for patients whose cancer has progressed despite other treatments.
Trials for EGFR Positive Patients
Alkylating agents
Amivantamab + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial will compare how effective amivantamab is at treating NSCLC with EGFR Exon 20ins mutations, compared to chemotherapy alone. The metric for success is progression-free survival (PFS).
Tyrosine Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests Lazertinib and Amivantamab for patients with advanced lung cancer with specific mutations. Lazertinib stops cancer cell growth, while Amivantamab helps the immune system kill these cells.
Alkylating agents
Amivantamab + Lazertinib + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial will compare the effectiveness of two different cancer treatments in people with lung cancer that has continued to grow despite treatment with osimertinib.
Phase 3 Trials
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Altamonte Springs, Florida
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
Alkylating agents
Amivantamab + Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial will compare how effective amivantamab is at treating NSCLC with EGFR Exon 20ins mutations, compared to chemotherapy alone. The metric for success is progression-free survival (PFS).
Platinum-based Chemotherapy
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Trials With No Placebo
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.